Analyst Scoreboard: 5 Ratings For Pacific Biosciences
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Pacific Biosciences (NASDAQ:PACB) over the last quarter, with 2 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target has declined to $3.3 from a previous $5.25. Recent analyst actions include Morgan Stanley lowering its target to $2.00 and Canaccord Genuity lowering its target to $3.00.
August 12, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacific Biosciences (NASDAQ:PACB) has received mixed analyst ratings over the last quarter, with a declining average 12-month price target now at $3.3. Recent actions include Morgan Stanley lowering its target to $2.00 and Canaccord Genuity lowering its target to $3.00.
The mixed ratings and significant reduction in price targets from major firms like Morgan Stanley and Canaccord Genuity suggest a bearish short-term outlook for PACB. The decline in the average price target from $5.25 to $3.3 indicates lowered expectations for the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100